Kisqali (ribociclib)

€5,016.00
In stock
SKU
Kisqali (ribociclib)

How to buy Kisqali (ribociclib): You can order Kisqali (ribociclib) from TheSocialMedwork if the medicine has not been approved or is not available in your country. We help patients and doctors get access to medicines at the lowest price worldwide.

Oncology Breast Cancer
Marketing Authorisation Holder Novartis Europharm Limited
Mode of Action Kinase inhibitor (targeted therapy)
Administration Oral
Regulatory agency approval European Medical Agency (EMA), European Union, Food and Drug Administration (FDA), USA, Therapeutic Goods Administration (TGA), Australia
Strength 200 milligram

What is Kisqali (ribociclib) for?

Kisqali (ribociclib) is a kinase inhibitor indicated in combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer1,2.

How does Kisqali (ribociclib) work?

Ribociclib is an inhibitor of cyclin-dependent kinase (CDK) 4 and 6. Before a cell can divide, it has to go through four phases: a growth phase (G1-phase), a synthesis phase (S-phase), another growth phase (G2-phase), and a last phase is where the cell divides (M-phase). Cancer cells divide exceedingly fast, passing through these 4 phases rapidly. Ribociclib blocks the progression from the first G1-phase, into the second S-phase. It does this by inhibiting the cyclin-dependent kinases 4 and 6 (CDK4 and CDK6) – two proteins that are involved in entering the S-phase1.

Where has Kisqali (ribociclib) been approved?

Kisqali (ribociclib) was approved in combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of postmenopausal women with HR-positive HER2-negative advanced or metastatic breast cancer by:

  • FDA (USA) on March 13, 20173

  • EMA (EU) on August 22, 20174

How is Kisqali (ribociclib) taken?

The standard dosage is:

  • 600 mg orally (three 200 mg tablets) taken once daily with or without food for 21 consecutive days, followed by 7 days off treatment (one complete cycle consists of 28 days).

  • Dose interruption, reduction, and/or discontinuation may be required based on individual safety and tolerability.

Complete information about Kisqali (ribociclib) dosage and administration can be found in the resources section.

Consult your treating doctor for personalised dosing.

Are there any known adverse reactions or side effects of Kisqali (ribociclib)

Most common adverse reactions (incidence ≥ 20%) are1,4:

  • low levels of white blood cells
  • nausea
  • fatigue
  • diarrhea
  • alopecia
  • vomiting
  • constipation
  • headache
  • back pain.
More Information
Working ingredient ribociclib
Shipping method Standard (not temperature controlled)
Therapeutic Area Oncology
Oncology Breast Cancer
Indication Chronic lymphocytic leukaemia (CLL) in the presence of 17p deletion or TP53 mutation, FLT3 mutation-positive acute myeloid leukemia (AML), Systemic mastocytosis, Multiple myeloma
Indication Deleterious or suspected deleterious gBRCAm, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (treatment)
Indication Anaplastic lymphoma kinase (ALK)-positive, metastatic non-small cell lung cancer (NSCLC), Metastatic NSCLC
Administration Oral
Mode of Action Kinase inhibitor (targeted therapy)
Regulatory agency approval European Medical Agency (EMA), European Union, Food and Drug Administration (FDA), USA, Therapeutic Goods Administration (TGA), Australia
Marketing Authorisation Holder Novartis Europharm Limited

The efficacy of Kisqali (ribociclib) was assessed in a randomised, double-blind, placebo-controlled, multicenter clinical study (MONALEESA-2) which compared ribociclib plus letrozole (N=334) to placebo plus letrozole (N=334) in a total of 668 postmenopausal women with HR-positive, HER2-negative, advanced breast cancer who received no prior therapy for advanced disease1,2.

The median progression-free survival (PFS) (at the 2/01/2017 cutoff) was 25.3 months ribociclib plus letrozole group (95% CI: 23.0, 30.3) and 16.0 months (95% CI 13.4, 18.2) in the placebo group. The overall response rate was 54.5% in the ribociclib plus letrozole group (95% CI: 48.4, 60.6) and  38.8% (95% CI 32.7, 44.9) in the placebo plus letrozole group2.


1. Summary of Product Characteristics [FDA]: Kisqali (ribociclib) [PDF]
    Novartis Pharmaceuticals Corporation, March 2017

2. Summary of Product Characteristics [EMA]: Kisqali (ribociclib) [PDF]
    Novartis Europharm Ltd, Aug 2017

3. Approved Drugs: Ribociclib (Kisqali)
    FDA, March 2017

4. Human Medicines: Kisqali (ribociclib)
    EMA, cited Oct 2017


Shipping Type Standard
Shipping method Standard (not temperature controlled)
This content has been reviewed by our medical doctor Jan de Witt.

How can we help you?

We're ready to answer any question!

Don't speak English? We also speak
Armenian, Bosnian, Bulgarian, Dutch, Filipino, German, Italian, Hebrew, Lithuanian, Portuguese, Russian, Serbian, Slovenian, Spanish, Swedish and Turkish.

 

Speak a different language?
Send us a message and we’ll do our best to translate.

 

Our guarantee: We will reply to all messages within 2 hours during office hours.

 

If you want to reach us via phone or chat, please visit our contact page

 

The Social Medwork is registered with the Dutch Ministry of Health in The Hague as an independent intermediary, Registration number 6730 BEM
100% legal and regulated
Registered with the Dutch Ministry of Health as an independent intermediary.

 

Registration number 6730 BEM
Secured logistics globally
• Standard and express delivery (DHL or UPS)
• 24/7 track & trace delivery
• Temperature regulated shipping
Secure payments
All payments are handled securely and are SSL encrypted.
We accept:
Bank transfer & Credit card

 

Patient reviews

 Tomasz Maćkowiak

During the transaction process I was very well informed by the TheSocialMedwork team. They have put as much of their effort to offer best service to me. Moreover the medicine I have ordered was imported two weeks earlier then it was expected. I highly recommend The Social Med Work.

Patient reviews

 Emina Mušović

Thank you for the wonderful cooperation! It's very reserved of us to say we're pleased because you really resolved all our doubts. The medicine has now arrived and we hope it helps. We know we were difficult, with the million different questions but well... That's all behind us now. Strongly recommended! :)

Patient reviews

 Mohamed Rahmat

I am fully satisfied with your online support service. Happy to deal with you.. fast & very fast support.. did not have to wait even 5 minutes! THANK YOU MEDWORK

Questions our patients are asking

visit our support page
You always need a prescription from a doctor based in your country. Other documents, such as an import license from the Ministry of Health, may be needed and depend on your country’s regulations. Contact us and we will provide you with all of the information about the required documents needed for your country.
For prescription medicines you will always need a prescription from your treating doctor. This is to ensure that your treatment is monitored and led by a doctor who is responsible for administering the medicine to you. The prescription is the evidence that your doctor gives you their medical support.
Your order will be shipped to you by our partner couriers, such as DHL, UPS and specialised medicine couriers. If you want us to use a specific courier please inform us when you place your order.
Yes. TheSocialMedwork is registered with the Dutch Ministry of Health as an independent medicines intermediary (registration number 6730 BEM). We always follow your country’s laws and regulations and will discuss any legal requirements with you. We only ship medicines when our patients have a prescription from their treating doctor.
By using TheSocialMedwork you will receive genuine medicines in perfect condition, no matter where you live.
Yes, you are welcome to visit us. We are located in the city centre of Amsterdam at the Herengracht 480. Contact us to schedule the best time for your visit.

 

You can order and receive your
medicine in 5 simple steps

1

Talk to your doctor

2

Place order
and send
prescription

3

Pay for order

4

Check documents
for delivery

5

Receive your medicine

Totally awesome!
Keep up the great
work you’re doing!


Dee Penfold - December 3, 2016
On TheSocialMedwork Facebook

Need a medicine that’s not
approved in your country?

We help patients, physicians and pharmacists acquire the latest life-changing medicines. Not available in your country? No problem - as long as it's approved by a reputable medical authority somewhere, we can help! Contact us today and our experienced team of qualified pharmacists and industry professionals will help you.


learn more
Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Medicine information contained herein may be time sensitive. The absence of a warning for a given medicine or combination thereof in no way should be construed to indicate that the medicine or combination is safe, effective or appropriate for any given patient. Always consult your treating physician before starting a course of treatment.